Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.

/in

Provine NM, Larocca RA, Penaloza-MacMaster P, Borducchi EN, McNally A, Parenteau LR, Kaufman DR, Barouch DH. Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses. J. Immunol. 2014; 192:5214-5225.

Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles.

/in

Goepfert PA, Elizaga ML, Seaton KE, et al.; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccine Trials Network (Dolin R). Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles. J Infect Dis. 2014 July;210(1):99-110. PMCID: PMC4072895.

Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens.

/in

Penaloza-MacMaster P, Teigler JE, Obeng RC, Kang ZH, Provine NM, Parenteau L, Blackmore S, Ra J, Borducchi EN, Barouch DH. Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens. J. Virol. 2014; 88:6243-6254.

Enhanced Immunogenicity of an HIV-1 DNA Vaccine Delivered with Electroporation via Combined Intramuscular and Intradermal Routes.

/in

Mann JF, McKay PF, Fiserova A, Klein K, Cope A, Rogers P, Swales J, Seaman MS, Combadiere B, Shattock RJ. Enhanced Immunogenicity of an HIV-1 DNA Vaccine Delivered with Electroporation via Combined Intramuscular and Intradermal Routes. J. Virol. 2014, 88(12):6959-69.

Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41.

/in

Chen J, Frey G, Peng H, Rits-Vollach S, Garrity J, Seaman MS, Chen B. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J. Virol. 2014, 88(2):1249-58.

Structural basis for nuclear import of splicing factors by human Transportin 3.

/in

Maertens GN, Cook N, Wang W, Hare S, Gupta SS, Oztop I, Lee K, Pye VE, Cosnefroy O, Snijders AP, KewalRamani VN, Fassati A, Engelman A, Cherepanov P. Structural basis for nuclear import of splicing factors by human Transportin 3. Proc Natl Acad Sci U S A 2014 Feb 18;111(7):2728-33. doi: 10.1073/pnas.1320755111. Epub 2014 Jan 21. PubMed PMID: 24449914; PubMed Central PMCID: PMC3932936.

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

/in

Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014, 158(6):1243-53.

First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 (IPCAVD 002).

/in , ,

Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP, Kleinjan JA, Gothing JA, Engelson BA, Carey BR, Oza A, Bajimaya S, Peter L, Bleckwehl C, Abbink P, Pau MG, Weijtens M, Kunchai M, Swann EM, Wolff M, Dolin R, Barouch DH. First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 (IPCAVD 002). J Infect Dis. 2014 Oct;210(7):1052-61. PMCID: PMC4168302.

Mechanisms, consequences, and treatment of chronic inflammation in HIV disease.

/in

Reeves, R. K. 2014. Mechanisms, consequences, and treatment of chronic inflammation in HIV disease. J. Antivir. Antiretrovir. 6:2. e117.

Structural insight into HIV-1 restriction by MxB.

/in

Fribourgh JL, Nguyen HC, Matreyek KA, Alvarez FJD, Summers BJ, Dewdney TG, Aiken C, Zhang P, Engelman A, Xiong Y. Structural insight into HIV-1 restriction by MxB. Cell Host Microbe 2014 Nov 12;16(5):627-38. doi: 10.1016/j.chom.2014.09.021. Epub 2014 Oct 9. PubMed PMID: 25312384; PubMed Central PMCID: PMC4252739.